Zai Lab Limited - American Depositary Shares (ZLAB) closed at $22.04 on October 22, 2026, down 8.9% from the previous close, on volume of 1,288,251 shares (30-day average 809,396).
Data as of October 22, 2026.
22-Oct-2026
Zai Lab announces $250M private placement
Seeking Alpha News (Fri, 23-Oct 2:26 AM ET)
Zai Lab Announces $250 Million Private Placement
Business Wire (Thu, 22-Oct 8:52 PM ET)
Business Wire (Wed, 21-Oct 7:30 AM ET)
TipRanks (Mon, 19-Oct 7:40 AM ET)
Business Wire (Wed, 14-Oct 7:00 AM ET)
Business Wire (Tue, 29-Sep 8:07 AM ET)
Business Wire (Mon, 17-Aug 6:00 AM ET)
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire (Thu, 6-Aug 6:30 AM ET)
Business Wire (Mon, 3-Aug 7:00 AM ET)
Market Chameleon (Mon, 20-Apr 3:52 AM ET)
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Zai Lab Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ZLAB.
As of October 22, 2026, ZLAB stock price declined to $22.04 with 1,288,251 million shares trading.
ZLAB has a beta of 1.85, meaning it tends to be more sensitive to market movements. ZLAB has a correlation of 0.16 to the broad based SPY ETF.
ZLAB has a market cap of $2.47 billion. This is considered a Mid Cap stock.
Last quarter Zai Lab Limited - American Depositary Shares reported $106 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.19.
In the last 3 years, ZLAB traded as high as $44.34 and as low as $13.48.
The top ETF exchange traded funds that ZLAB belongs to (by Net Assets): IBB, CANC, SBIO, BBP, PGJ.
ZLAB has underperformed the market in the last year with a price return of -24.4% while the SPY ETF gained +14.9%. However, in the short term, ZLAB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.6% vs +2.3% return in SPY. But in the last 2 weeks, ZLAB shares have been beat by the market, returning -12.9% compared to an SPY return of -1.7%.
ZLAB support price is $23.32 and resistance is $25.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZLAB shares will trade within this expected range on the day.
